Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company's lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because of a limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts.
Bioxytran (OTCQB: BIXT) has formed a Joint Venture with the Heme Foundation to develop a Universal Oxygen Carrier (UOC) as an alternative to blood transfusions. The Foundation pledged up to $10 million for the project, with $2 million already invested in prototypes and compound development. Bioxytran retains all intellectual property rights, while the Foundation gains usage rights for blood transfusion applications.
The UOC, a hemoglobin-based oxygen carrier, is designed to be compatible with all blood types, pathogen-free, and shelf-stable at room temperature for 5+ years. It has shown promise in small-scale animal trials and is preparing for a large-scale toxicology study. This technology could revolutionize transfusion medicine, particularly in remote areas with blood supply infrastructure.
Bioxytran's Science Advisor, Prof. Avraham Mayevsky, has published a book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions. The book, available as an eBook or hardcover from Springer, delves into the impact of hyperbaric oxygen on brain functions, particularly mitochondrial activity.
Central to the book is the MDX Viewer, an FDA-approved device that measures tissue oxygenation at the cellular level. The device's output, the Brain Metabolic Score (BMS), is essential for Bioxytran's acellular oxygen carrier (AOC) molecule, BXT-25, which is being developed for ischemic stroke and Alzheimer's disease treatments. Bioxytran aims to use BXT-25 to replace hyperbaric oxygen treatment (HBOT) in clinical trials.
The book offers a comprehensive overview of how hyperbaric oxygen impacts brain biochemical and physiological responses, influencing mitochondrial activity and enhancing brain functions.
FAQ
What is the focus of Bioxytran, Inc.?
What is the lead pharmaceutical drug candidate of the company?
What is BXT-252?
When was Bioxytran, Inc. founded?
Where is Bioxytran, Inc. headquartered?
What are the contact details for Investor Relations at Bioxytran, Inc.?
What recent achievement has Bioxytran, Inc. made in lesion clearance and regression of Herpes Zoster Neuralgia?
What does the company's patent cover?
What products are included in Bioxytran, Inc.'s portfolio?
What kind of therapeutic drugs does Bioxytran, Inc. manufacture?
